US researchers develop test vaccine that prevents development of prostate cancer in mice.

At AusBiotech's targeting tumours session next week, Minomic's CEO, Brad Walsh, will explain how proteomics can be harnessed to diagnose disease.

B7-H3 identified as biomarker to predict cancer recurrence and progression.

A team of Brisbane researchers is using high-throughput protein analysis to take a closer look at the molecular and cellular basis of prostate cancer.

700 Rottweilers will assist American researchers to discover whether antioxidant supplementation has a preventative effect in bone cancer.

A team at Monash Institute of Medical Research in Melbourne has grown a human prostate from embryonic stem cells, and hopes the discovery will lead to better understanding of what causes prostate cancer.

John Chiplin, the new CEO of Sydney biopharma Peptech (ASX:PTD), sees strong similarities between the state of Australia's biotechnology industry and California's nascent biotechnology industry in San Diego in the mid-1980s.

Trials of Novogen's (ASX:NRT) anti-cancer drug phenoxodiol have shown it significantly delays tumour progression in men suffering from late-stage hormone refractory prostate cancer and produces anti-cancer responses in women with cervical cancer.

Sydney peptide therapeutics company Peptech (ASX:PTD) has reported positive results from a trial of a prostate cancer diagnostic developed by its joint-venture partner Biosceptre International.

Jim Bishop, CEO of the Cancer Institute NSW, spoke about the state of play at the Institute 18 months after its launch, the progress it has made so far and its plans for the coming year at in Sydney last week.

Cancer therapeutics company Australian Cancer Technology (ASX:ACU) announced today its GPI-0100 vaccine adjuvant has produced an enhanced immune response in its Phase I clinical trial in men with relapsed prostate cancer.